Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

NCT00378833 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1300

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia
Hyperlipidemia

Interventions

DRUG: niacin (+) laropiprant
DRUG: niacin

Sponsor

Merck Sharp & Dohme LLC